These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Rahaghi FF; Monk R; Ramakrishnan V; Beiko T; Strange C Int J Chron Obstruct Pulmon Dis; 2020; 15():3193-3199. PubMed ID: 33299307 [TBL] [Abstract][Full Text] [Related]
7. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Sclar DA; Evans MA; Robison LM; Skaer TL Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280 [TBL] [Abstract][Full Text] [Related]
8. Patterns and characterization of COPD exacerbations using real-time data collection. Ejiofor SI; Stolk J; Fernandez P; Stockley RA Int J Chron Obstruct Pulmon Dis; 2017; 12():427-434. PubMed ID: 28182151 [TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Wencker M; Banik N; Buhl R; Seidel R; Konietzko N Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Qaseem A; Wilt TJ; Weinberger SE; Hanania NA; Criner G; van der Molen T; Marciniuk DD; Denberg T; Schünemann H; Wedzicha W; MacDonald R; Shekelle P; ; ; ; Ann Intern Med; 2011 Aug; 155(3):179-91. PubMed ID: 21810710 [TBL] [Abstract][Full Text] [Related]
11. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324 [TBL] [Abstract][Full Text] [Related]
13. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Campos MA; Alazemi S; Zhang G; Wanner A; Salathe M; Baier H; Sandhaus RA Respir Med; 2009 Oct; 103(10):1532-9. PubMed ID: 19464158 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Wencker M; Fuhrmann B; Banik N; Konietzko N; Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951 [TBL] [Abstract][Full Text] [Related]
15. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. Vijayasaratha K; Stockley RA Int J Chron Obstruct Pulmon Dis; 2012; 7():789-96. PubMed ID: 23226015 [TBL] [Abstract][Full Text] [Related]
16. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706 [TBL] [Abstract][Full Text] [Related]
17. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Demeo DL; Sandhaus RA; Barker AF; Brantly ML; Eden E; McElvaney NG; Rennard S; Burchard E; Stocks JM; Stoller JK; Strange C; Turino GM; Campbell EJ; Silverman EK Thorax; 2007 Sep; 62(9):806-13. PubMed ID: 17389752 [TBL] [Abstract][Full Text] [Related]
18. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Kueppers F Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542 [TBL] [Abstract][Full Text] [Related]
19. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Abboud RT; Ford GT; Chapman KR; Can Respir J; 2001; 8(2):81-8. PubMed ID: 11320399 [TBL] [Abstract][Full Text] [Related]
20. Augmentation therapy for alpha-1 antitrypsin deficiency--not enough evidence to support its use yet! McCarthy C; Dimitrov BD COPD; 2010 Jun; 7(3):234; author reply 235-6. PubMed ID: 20486824 [No Abstract] [Full Text] [Related] [Next] [New Search]